Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Market Cap	3.71B
Revenue (ttm)	130.70M
Net Income (ttm)	14.51M
Shares Out	50.53M
EPS (ttm)	0.36
PE Ratio	203.89
Forward PE	n/a
Dividend	0.09 (0.12%)
Ex-Dividend Date	Aug 25, 2025

Volume	95,386
Average Volume	145,669
Open	70.00
Previous Close	71.10
Day's Range	70.00 - 73.40
52-Week Range	31.65 - 76.30
Beta	n/a
RSI	79.71
Earnings Date	n/a

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7762

Financial Performance

In 2024, Pet Pharm Biotech's revenue was 130.70 million, an increase of 10.89% compared to the previous year's 117.87 million. Earnings were 14.51 million, an increase of 58.54%.